Loading...
600572 logo

Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE:600572 Stock Report

Market Cap CN¥12.1b
Share Price
CN¥4.80
My Fair Value
n/a
1Y-2.8%
7D1.7%
Portfolio Value
View

Zhejiang CONBA Pharmaceutical Co.,Ltd.

SHSE:600572 Stock Report

Market Cap: CN¥12.1b

Zhejiang CONBA PharmaceuticalLtd (600572) Stock Overview

Engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. More details

600572 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends5/6

600572 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Zhejiang CONBA Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang CONBA PharmaceuticalLtd
Historical stock prices
Current Share PriceCN¥4.80
52 Week HighCN¥5.03
52 Week LowCN¥4.16
Beta0.28
1 Month Change8.60%
3 Month Change2.78%
1 Year Change-2.83%
3 Year Change5.03%
5 Year Change-5.51%
Change since IPO201.40%

Recent News & Updates

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

Nov 05
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Sep 30
It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Sep 12
Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Aug 20
Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21
Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Shareholder Returns

600572CN PharmaceuticalsCN Market
7D1.7%-1.8%0.6%
1Y-2.8%12.3%16.2%

Return vs Industry: 600572 underperformed the CN Pharmaceuticals industry which returned 12.3% over the past year.

Return vs Market: 600572 underperformed the CN Market which returned 16.2% over the past year.

Price Volatility

Is 600572's price volatile compared to industry and market?
600572 volatility
600572 Average Weekly Movement2.0%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement5.5%
10% most volatile stocks in CN Market9.4%
10% least volatile stocks in CN Market3.0%

Stable Share Price: 600572 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600572's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19698,411Guoliang Luowww.conbapharm.com

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products.

Zhejiang CONBA Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Zhejiang CONBA PharmaceuticalLtd's earnings and revenue compare to its market cap?
600572 fundamental statistics
Market capCN¥12.07b
Earnings (TTM)CN¥687.99m
Revenue (TTM)CN¥6.58b
17.6x
P/E Ratio
1.8x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600572 income statement (TTM)
RevenueCN¥6.58b
Cost of RevenueCN¥3.13b
Gross ProfitCN¥3.45b
Other ExpensesCN¥2.76b
EarningsCN¥687.99m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin52.46%
Net Profit Margin10.46%
Debt/Equity Ratio5.6%

How did 600572 perform over the long term?

See historical performance and comparison

Dividends

3.1%
Current Dividend Yield
55%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/11 15:55
End of Day Share Price 2025/11/11 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang CONBA Pharmaceutical Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weina JiangEverbright Securities Co. Ltd.
Wenxin YuHaitong International Research Limited
Hai Zhu PengHuatai Research